Chimerix Announces Brincidofovir Suggests Favorable Resistance Profile in Adenovirus, CMV
September 08, 2014 at 16:02 PM EDT
Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, ...